Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 4/2017

01-04-2017 | Letter to the Editor

Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy

Authors: Nicolas Belhomme, Adel Maamar, Thomas Le Gallou, Marie-Christine Minot-Myhié, Antoine Larralde, Nicolas Champtiaux, Olivier Benveniste, Sarah Leonard-Louis, Olivier Decaux, Alain Lescoat, Yves Le Tulzo

Published in: Annals of Hematology | Issue 4/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Doppler K, Knop S, Einsele H, Sommer C, Wessig C (2013) Sporadic late onset nemaline myopathy and immunoglobulin deposition disease. Muscle Nerve 48:983–988CrossRefPubMed
2.
Voermans NC, Benveniste O, Minnema MC, Lokhorst H, Lammens M, Meersseman W et al (2014) Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCT. Neurology 83:2133–2139CrossRefPubMed
3.
Finsterer J, Stöllberger C (2015) Review of cardiac disease in nemaline myopathy. Pediatr Neurol 53(6):473–477CrossRefPubMed
Metadata
Title
Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy
Authors
Nicolas Belhomme
Adel Maamar
Thomas Le Gallou
Marie-Christine Minot-Myhié
Antoine Larralde
Nicolas Champtiaux
Olivier Benveniste
Sarah Leonard-Louis
Olivier Decaux
Alain Lescoat
Yves Le Tulzo
Publication date
01-04-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 4/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2916-3

Other articles of this Issue 4/2017

Annals of Hematology 4/2017 Go to the issue

Letter to the Editor

Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate

Original Article

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

Letter to the Editor

Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia

Letter to the Editor

Vaccination of allogeneic hematopoietic stem cell transplant recipients—what should be considered?

Original Article

Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab

Review Article

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits